NOVEMBER - 202019across near, intermediate, and far distances. "At AcuFocus, we provide superior outcomes and consistent satisfaction to both patients and physicians, with our proven and reliable technologies," states Alan (Al) Waterhouse, the CEO and President of AcuFocus.The IC-8 IOL is approved for use outside the United States and is available in select European and Asian markets. The implant is currently undergoing an Investigational Device Exemption clinical study in the U.S. It has previously been shown to provide up to 3.00 D of continuous, extended depth of focus and manage as much as 1.50 D of preoperative corneal astigmatism5-8. Additionally, the unique IOL is designed to reduce the effects of lower- and higher-order aberrations that have been reported as side effects associated with multifocal technology. In spite of the number of IOL technologies on the market, not all patients qualify for, or are candidates for advanced technology IOL implants. Multifocal technologies use complex optical designs to achieve the desired outcome, an approach that can come with complications such as glare and halo that some patients find distracting.9 The IC-8 IOL is a novel solution based on a well understood, age-old concept of pinhole optics. By virtue of its design, it is not associated with significant photic phenomena. This makes it an easy-to-use solution for a broad range of patients, many of whom are not candidates for other advanced technology IOLs.Even as a new entrant in this space, AcuFocus has a strong and experienced team of ophthalmology professionals who play a crucial role in ensuring access to the IC-8 globally. The company also has reliable financial backing from its partnerships with KKR & Co. Inc., one of the world's leading investment firms, along with Flying L Partners. With its first commercial launch in the U.S market, the company will be investing in R&D of other advances of the small aperture platform to better physicians--and patients--across the globe. At AcuFocus, we provide superior outcomes and consistent satisfaction to both patients and physicians, with our proven and reliable technologies.1. Davis Geetha. The Evolution of Cataract Surgery. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139750/ Mo Med. 2016 Jan-Feb; 113(1): 5862. PMID: 270394932. American Academy of Ophthalmology. Cataract Surgery Infographic. https://www.aao.org/eye-health/news/cataract-surgery-infographic.3. iData Research. Over 3.8 million cataract surgeries performed every year. April 6, 2018. https://idataresearch.com/over-3-8-million-cataract-surgeries-performed-every-year/4. Market Scope. 2018 IOL Report.5. Data on file at AcuFocus, Inc. 6. Dick HB, Piovella M, Vukich J, et al. Prospective multicenter trial of a small-aperture intraocular lens in cataract surgery. J Cataract Refract Surg. 2017;43(7):956-968. doi:10.1016/j.jcrs.2017.04.038.7. RE Ang. Small-aperture intraocular lens tolerance to induced astigmatism. Clin Ophthalmol 2018;12:1659-1664. 8. RE Ang. Comparison of tolerance to induced astigmatism in pseudophakic eyes implanted with small aperture, trifocal, or monofocal intraocular lenses. Clin Ophthalmol. 2019;13: 905.9. Hovanesian JA, Lane SS, Allen QB, Jones M. Patient-reported outcomes/satisfaction and spectacle independence with blended or bilateral multifocal intraocular lenses in cataract surgery. Clin Ophthalmol. 2019; 13: 25912598.doi: 10.2147/OPTH.S227629.
<
Page 9 |
Page 11 >
